Literature DB >> 12522132

Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin II-induced trans-activation of the epidermal growth factor receptor.

Koichi Seta1, Junichi Sadoshima.   

Abstract

Although tyrosine kinases are critically involved in the angiotensin II (Ang II) type 1 (AT1) receptor signaling, how AT1 receptors activate tyrosine kinases is not fully understood. We examined the structural requirements of the AT1 receptor for transactivation of the epidermal growth factor (EGF) receptor (EGFR). Studies using carboxyl terminal-truncated AT1 receptors indicated that the amino acid sequence between 312 and 337 is required for activation of EGFR. The role of the conserved YIPP motif in this sequence in transactivation of EGFR was investigated by mutating tyrosine 319. Ang II failed to activate EGFR in cells expressing AT1-Y319F, whereas EGFR was activated even without Ang II in cells expressing AT1-Y319E, which mimics the AT1 receptor phosphorylated at Tyr-319. Immunoblot analyses using anti-phospho Tyr-319-specific antibody showed that Ang II increased phosphorylation of Tyr-319. EGFR interacted with the AT1 receptor but not with AT1-Y319F in response to Ang II stimulation, whereas the EGFR-AT1 receptor interaction was inhibited in the presence of dominant negative SHP-2. The requirement of Tyr-319 seems specific for EGFR because Ang II-induced activation of other tyrosine kinases, including Src and JAK2, was preserved in cells expressing AT1-Y319F. Extracellular signal-regulated kinase activation was also maintained in AT1-Y319F through activation of Src. Overexpression of wild type AT1 receptor in cardiac fibroblasts enhanced Ang II-induced proliferation. By contrast, overexpression of AT1-Y319F failed to enhance cell proliferation. In summary, Tyr-319 of the AT1 receptor is phosphorylated in response to Ang II and plays a key role in mediating Ang II-induced transactivation of EGFR and cell proliferation, possibly through its interaction with SHP-2 and EGFR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12522132     DOI: 10.1074/jbc.M208017200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  S-nitrosylation of cysteine 289 of the AT1 receptor decreases its binding affinity for angiotensin II.

Authors:  Patrice C Leclerc; Pascal M Lanctot; Mannix Auger-Messier; Emanuel Escher; Richard Leduc; Gaetan Guillemette
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

Review 3.  Diversity in arrestin function.

Authors:  Ryan T Kendall; Louis M Luttrell
Journal:  Cell Mol Life Sci       Date:  2009-07-12       Impact factor: 9.261

Review 4.  G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function.

Authors:  Douglas G Tilley
Journal:  Circ Res       Date:  2011-07-08       Impact factor: 17.367

5.  Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice.

Authors:  Peiyong Zhai; Mitsutaka Yamamoto; Jonathan Galeotti; Jing Liu; Malthi Masurekar; Jill Thaisz; Keiichi Irie; Eric Holle; Xianzhong Yu; Sabina Kupershmidt; Dan M Roden; Thomas Wagner; Atsuko Yatani; Dorothy E Vatner; Stephen F Vatner; Junichi Sadoshima
Journal:  J Clin Invest       Date:  2005-11       Impact factor: 14.808

Review 6.  Cardiac GPCR-Mediated EGFR Transactivation: Impact and Therapeutic Implications.

Authors:  Laurel A Grisanti; Shuchi Guo; Douglas G Tilley
Journal:  J Cardiovasc Pharmacol       Date:  2017-07       Impact factor: 3.105

7.  A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation.

Authors:  Amee J George; Brooke W Purdue; Cathryn M Gould; Daniel W Thomas; Yanny Handoko; Hongwei Qian; Gregory A Quaife-Ryan; Kylie A Morgan; Kaylene J Simpson; Walter G Thomas; Ross D Hannan
Journal:  J Cell Sci       Date:  2013-09-17       Impact factor: 5.285

8.  Central role of Gq in the hypertrophic signal transduction of angiotensin II in vascular smooth muscle cells.

Authors:  Haruhiko Ohtsu; Sadaharu Higuchi; Heigoro Shirai; Kunie Eguchi; Hiroyuki Suzuki; Akinari Hinoki; Eugen Brailoiu; Andrea D Eckhart; Gerald D Frank; Satoru Eguchi
Journal:  Endocrinology       Date:  2008-03-20       Impact factor: 4.736

9.  Mechanism and functional significance of Itk autophosphorylation.

Authors:  Raji E Joseph; D Bruce Fulton; Amy H Andreotti
Journal:  J Mol Biol       Date:  2007-08-31       Impact factor: 5.469

10.  Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System.

Authors:  Steven J Forrester; Tatsuo Kawai; Shannon O'Brien; Walter Thomas; Raymond C Harris; Satoru Eguchi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-11-09       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.